Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma
Abstract Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular carcinoma (HCC). However, the long-...
Saved in:
Main Authors: | Zhaosong Xue, Ming Yao, Kang Chen, Taiyun Huang, Jianjun Li, Jian Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-025-88813-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01) -
Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01) -
Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01) -
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01) -
Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression
by: Liqin Ruan, et al.
Published: (2025-02-01)